Surgical management in metastatic gastrointestinal stromal tumor (GIST) patients after imatinib mesylate treatment

Yeh, Chun‐Nan; Chen, Tsung-Wen; Tseng, Jeng‐Hwei; Liu, Yuyin; Wang, Shang‐Yu; Tsai, Chun‐Yi; Chiang, Kun‐Chun; Hwang, Tsann‐Long; Jan, Yi-Yin; Chen, Miin‐Fu

doi:10.1002/jso.21630

Cited by 50 publications

(32 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…If those lesions are not removable, escalation of the dose of imatinib or a switch to sunitinib should be considered. Although there was no prospective study to evaluate the efficacy of local treatment for focal progression in GIST, retrospective analyses have suggested that some cases with focal progression may benefit from local treatment [38,60]. On the other hand, there was a study showing the potential risk of rapid disease progression within a short period of time after local treatment [39].…”

Section: Medical Treatment Of Gistsmentioning

confidence: 99%

Asian Consensus Guidelines for the Diagnosis and Management of Gastrointestinal Stromal Tumor

Koo

Ryu²,

Kim³

et al. 2016

Cancer Res Treat

Self Cite

156

194

View full text Add to dashboard Cite

Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors originating in the gastrointestinal tract. With the introduction of molecular-targeted therapy for GISTs which has yielded remarkable outcomes, these tumors have become a model of multidisciplinary oncological treatment. Although Western clinical guidelines are available for GISTs, such as those published by the National Comprehensive Cancer Network (NCCN) and the European Society of Medical Oncology (ESMO), the clinical situations in Asian countries are different from those in Western countries in terms of diagnostic methods, surgical approach, and availability of new targeted agents. Accordingly, we have reviewed current versions of several GIST guidelines published by Asian countries (Japan, Korea, China, and Taiwan) and the NCCN and ESMO and discussed the areas of dissensus. We here present the first version of the Asian GIST consensus guidelines that were prepared through a series of meetings involving multidisciplinary experts in the four countries. These guidelines provide an optimal approach to the diagnosis and management of GIST patients in Asian countries.

show abstract

Section: Medical Treatment Of Gistsmentioning

confidence: 99%

Asian Consensus Guidelines for the Diagnosis and Management of Gastrointestinal Stromal Tumor

Koo

Ryu²,

Kim³

et al. 2016

Cancer Res Treat

Self Cite

156

194

View full text Add to dashboard Cite

show abstract

“…It is also indicated in those who have a widespread metastatic disease or a recurrence after resection. There is a survival benefit of cytoreductive surgery following preoperative imatinib in patients responding to preoperative imatinib [51,[55][56][57][58][59][60][61][62] . The lesion is assessed within 3 mo of initiating therapy to determine if it has become resectable.…”

Section: Unresectable Metastatic or Recurrent Diseasementioning

confidence: 99%

“…In cases where the tumor remains unresectable, imatinib is continued indefinitely until there is evi- dence of tumor progression. Continuation of TKI therapy life-long for palliation of symptoms forms an essential component of best supportive care [9,18,27,29,51,[56][57][58][59][60][61][62] . Options for patients with progressive disease or with widespread systemic disease and good performance status (0-2) include continuation of imatinib at the same dose, dose escalation up to 800 mg in the absence of severe adverse drug reactions or switching to sunitinib [29,[44][45][46]51,53,55] .…”

Section: Unresectable Metastatic or Recurrent Diseasementioning

confidence: 99%

A gist of gastrointestinal stromal tumors: A review

Rammohan¹,

Sathyanesan²,

Rajendran³

et al. 2012

WJGO

149

193

View full text Add to dashboard Cite

enchymal tumors. Both traditional and minimally invasive surgery are used to remove these tumors with minimal morbidity and excellent perioperative outcomes. The revolutionary use of specific, molecularlytargeted therapies, such as imatinib mesylate, reduces the frequency of disease recurrence when used as an adjuvant following complete resection. Neoadjuvant treatment with these agents appears to stabilize disease in the majority of patients and may reduce the extent of surgical resection required for subsequent complete tumor removal. The important interplay between the molecular genetics of GIST and responses to targeted therapeutics serves as a model for the study of targeted therapies in other solid tumors. This review summarizes our current knowledge and recent advances regarding the histogenesis, pathology, molecular biology, the basis for the novel targeted cancer therapy and current evidence based management of these unique tumors. AbstractGastrointestinal stromal tumors (GISTs)

show abstract

“…It is believed to occur through development of a secondary acquired KIT mutation [19]. Sunitinib another molecule inhibitor of receptor tyrosine kinases has been shown to be an effective second-line therapy for patients with GISTs [20,21].…”

Section: Fine-needle Biopsymentioning

confidence: 99%

Gastrointestinal Stromal Tumours: Review of 150 Cases from a Single Centre

2013

View full text Add to dashboard Cite

Gastrointestinal stromal tumours (GIST) are the most common mesenchymal tumours of the gastrointestinal tract. They constitute a significant percentage ranging from 1-2 % of all the gastrointestinal neoplasms [11]. Knowledge on the molecular biology and behavior of these tumours is still not very clear. The clinicopathologial features are variable and surgical resection with chemotherapy is the main modality of treatment. We have retrospectively analyzed the clinicopathological features, treatment and prognosis of 150 patients managed in the Department of Surgery. Retrospective review of the records of 150 patients diagnosed with gastrointestinal stromal tumours and managed during the period January 2006 to December 2011. Clinicopathological features, immunohistochemistry, mitotic index, surgical resection adjuvant chemotherapy and survival analyzed. One hundred and fifty patients diagnosed with GIST and treated were reviewed. Ninety five of them were males (63.3 %). The tumour was most commonly seen during the fourth and fifth decades of life. Abdominal pain (52 %), intestinal bleeding (40 %) and abdominal mass (25 %) were the common clinical symptoms. Sixty percent of the tumours (90/150) were located in the stomach followed by small bowel (20 %) and duodenum (14.6 %). One hundred and thirty-five patients underwent excision of the tumour and five patients had multi organ resection of the adjacent organs like spleen, tail of the pancreas and kidney.

show abstract

Surgical management in metastatic gastrointestinal stromal tumor (GIST) patients after imatinib mesylate treatment

Cited by 50 publications

References 20 publications

Asian Consensus Guidelines for the Diagnosis and Management of Gastrointestinal Stromal Tumor

Asian Consensus Guidelines for the Diagnosis and Management of Gastrointestinal Stromal Tumor

A gist of gastrointestinal stromal tumors: A review

Gastrointestinal Stromal Tumours: Review of 150 Cases from a Single Centre

Contact Info

Product

Resources

About